%PDF-1.4
%
19 0 obj
<>
endobj
61 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-11-22T17:39:28Z
2024-03-28T14:12:53-07:00
QuarkXPressª: LaserWriter 8.5.1 8.5.1
2024-03-28T14:12:53-07:00
application/pdf
Heather
991290.march
uuid:c65c0fd6-1dd1-11b2-0a00-4709275d6100
uuid:c65c0fd9-1dd1-11b2-0a00-aa0000000000
endstream
endobj
17 0 obj
<>
endobj
20 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
1 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
4 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
7 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
10 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
75 0 obj
[78 0 R]
endobj
76 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.06 612 -792 re
W n
/CS0 CS 0 0 0 SC
54 54 m
558 54 l
S
BT
/CS0 cs 0 0 0 sc
/T1_0 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 424.3613 35.9844 Tm
(The Journal of Rheumatology 2001; 28:3)Tj
0 Tc 0 Tw -46.2952 -0.0313 Td
(524)Tj
ET
1 1 1 sc
102.25 59.08 407.5 -10.83 re
f*
0.5 w
102.25 59.08 407.5 -10.83 re
S
BT
0 0 0 sc
/T1_1 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 74.4 714.5293 Tm
(are associated with a history of thromboembolic complications in)Tj
0 -1.25 TD
(patients with SLE and primary antiphospholipid syndrome. Br J)Tj
T*
(Rheumatol 1995;34:1031-6.)Tj
-2.175 -1.25 Td
[(19.)-875.1 (Balestrieri G, )17.7 (T)35 (incani )54.8 (A, Spatola L, et al. )54.8 (Anti-\247)]TJ
0 Tc 0 Tw 5.2 0 0 5.2 228.9087 681.8893 Tm
(2)Tj
-0.00011 Tc 0.02499 Tw 8 0 0 8 231.5087 684.5293 Tm
(-glycoprotein I)Tj
-19.6386 -1.25 Td
(antibodies: a marker of antiphospholipid syndrome? Lupus)Tj
0 Tc 0 Tw T*
(1995;4:122-30.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(20.)-875.1 (Cabiedes J, Cabral )54.8 (AR, )54.8 (Alarcon-Segovia D. Clinical manifestations)]TJ
2.175 -1.25 Td
(of the antiphospholipid syndrome in patients with systemic lupus)Tj
T*
(erythematosus associate more strongly with anti-\247)Tj
0 Tc 0 Tw 5.2 0 0 5.2 236.0094 631.8893 Tm
(2)Tj
-0.00011 Tc 8 0 0 8 238.6094 634.5293 Tm
(-glycoprotein-I)Tj
0.02499 Tw -20.5262 -1.25 Td
(than with antiphospholipid antibodies. J Rheumatol 1995;)Tj
0 Tc 0 Tw T*
(22:1899-906.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(21.)-875.1 (Martinuzzo ME, Forastiero RR, Carreras LO. )54.8 (Anti-\247)]TJ
0 Tc 0 Tw 5.2 0 0 5.2 243.3622 601.8893 Tm
(2)Tj
-0.00011 Tc 0.02499 Tw 8 0 0 8 245.9622 604.5293 Tm
(-glycoprotein I)Tj
-21.4453 -1.25 Td
(antibodies: detection and association with thrombosis. Br J)Tj
T*
(Haematol 1995;89:397-402.)Tj
-2.175 -1.25 Td
[(22.)-875.1 (T)69.9 (an EM, Cohen )54.8 (AS, Fries JF)79.7 (, et al. )17.7 (The 1982 revised criteria for the)]TJ
2.175 -1.25 Td
[(classification of systemic lupus erythematosus. )54.8 (Arthritis Rheum)]TJ
0 Tc 0 Tw T*
(1982;25:1271-7.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(23.)-875.1 (Special report from the National Institute of Neurological Disorders)]TJ
2.175 -1.25 Td
(and Stroke: classification of cerebrovascular diseases, III. Stroke)Tj
0 Tc 0 Tw T*
(1990;21:637-76.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(24.)-875.1 (Harris EN, Gharavi )54.8 (AE, Patel SP)110.7 (, Hughes GR. Evaluation of the)]TJ
2.175 -1.25 Td
(anti-cardiolipin antibody test: report of an international workshop)Tj
T*
[(held 4 )54.8 (April 1986. Clin Exp Immunol 1987;68:215-22.)]TJ
-2.175 -1.25 Td
[(25.)-875.1 (Guerin J, Feighery C, Sim RB, Jackson J. )54.8 (Antibodies to \247)]TJ
0 Tc 0 Tw 5.2 0 0 5.2 259.9806 481.8893 Tm
(2)Tj
8 0 0 8 262.5806 484.5293 Tm
(-)Tj
-0.00011 Tc 0.02499 Tw -23.5226 -1.25 Td
(glycoprotein I \321 a specific marker for the antiphospholipid)Tj
T*
(syndrome. Clin Exp Immunol 1997;109:304-9.)Tj
-2.175 -1.25 Td
[(26.)-875.1 (Kalunian KC, Peter JB, Middlekauf)17.7 (f HR, et al. Clinical significance)]TJ
2.175 -1.25 Td
(of a single test for anti-cardiolipin antibodies in patients with)Tj
T*
[(systemic lupus erythematosus. )54.8 (Am J Med 1988;85:602-8.)]TJ
30.825 35 Td
[(27.)-875.1 (Gharavi )54.8 (AE, Harris EN, )54.8 (Asherson RA, Hughes GR. )54.8 (Anticardiolipin)]TJ
2.175 -1.25 Td
[(antibodies: isotype distribution and phospholipid specificity)64.8 (. )54.8 (Ann)]TJ
T*
(Rheum Dis 1987;46:1-6.)Tj
-2.175 -1.25 Td
[(28.)-875.1 (T)69.9 (sutsumi )54.8 (A, Matsuura E, Ichikawa K, Fujisaku )54.8 (A, Mukai M, Koike)]TJ
2.175 -1.25 Td
[(T)74 (. IgA)-220.2 (class anti-\247)]TJ
0 Tc 0 Tw 5.2 0 0 5.2 397.4981 671.8893 Tm
(2)Tj
-0.00011 Tc 0.02499 Tw 8 0 0 8 400.098 674.5293 Tm
(-glycoprotein I in patients with systemic lupus)Tj
-7.7123 -1.25 Td
(erythematosus. J Rheumatol 1998;25:74-8.)Tj
-2.175 -1.25 Td
[(29.)-875.1 (Molina JF)79.7 (, Gutierrez-Urena S, Molina J, et al. )17.7 (V)110.8 (ariability of )]TJ
2.175 -1.25 Td
(anticardiolipin antibody isotype distribution in 3 geographic)Tj
T*
(populations of patients with systemic lupus erythematosus. )Tj
T*
(J Rheumatol 1997;24:291-6.)Tj
-2.175 -1.25 Td
[(30.)-875.1 (Cucurull E, Gharavi )54.8 (AE, Diri E, Mendez E, Kapoor D, Espinoza)]TJ
2.175 -1.25 Td
[(LR. IgA)-220.2 (anticardiolipin and anti-\247)]TJ
0 Tc 0 Tw 5.2 0 0 5.2 448.2801 601.8893 Tm
(2)Tj
-0.00011 Tc 0.02499 Tw 8 0 0 8 450.8801 604.5293 Tm
(-glycoprotein I are the most)Tj
-14.06 -1.25 Td
[(prevalent isotypes in )54.8 (African )54.8 (American patients with systemic lupus)]TJ
T*
[(erythematosus. )54.8 (Am J Med Sci 1999;318:55-60.)]TJ
-2.175 -1.25 Td
[(31.)-875.1 (Guglielmone HA, Fernandez EJ. Distribution of lupus anticoagulant)]TJ
2.175 -1.25 Td
(and anticardiolipin antibody isotypes in a population with)Tj
T*
(antiphospholipid syndrome. J Rheumatol 1999;26:86-90.)Tj
-2.175 -1.25 Td
[(32.)-875.1 (Alarcon-Segovia D, Mestanza M, Cabiedes J, Cabral )54.8 (AR. )17.7 (The)]TJ
2.175 -1.25 Td
[(antiphospholipid/cofactor syndromes. II. )54.8 (A)-220.1 (variant in patients with)]TJ
T*
(systemic lupus erythematosus with antibodies to \247)Tj
0 Tc 0 Tw 5.2 0 0 5.2 500.4555 521.8893 Tm
(2)Tj
-0.00011 Tc 0.02499 Tw 8 0 0 8 503.0555 524.5293 Tm
(-glycoprotein I)Tj
-20.5819 -1.25 Td
(but no antibodies detectable in standard antiphospholipid assays. )Tj
T*
(J Rheumatol 1997;24:1545-51.)Tj
-2.175 -1.25 Td
[(33.)-875.1 (Picillo U, Marcialis MR, Italiano G. )54.8 (Antibodies to \247)]TJ
0 Tc 0 Tw 5.2 0 0 5.2 506.0122 491.8893 Tm
(2)Tj
-0.00011 Tc 0.02499 Tw 8 0 0 8 508.6122 494.5293 Tm
(-glycoprotein I)Tj
-21.2765 -1.25 Td
(in anticardiolipin negative patients. J Rheumatol 1998;25:1440-2.)Tj
ET
Q
Q
q
0 0 612 792 re
W n
BT
0 g
/GS1 gs
/T1_2 8 Tf
120.092 51 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2001. All rights reserved.)Tj
ET
Q
BT
0 g
/GS1 gs
/T1_3 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS1 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS1 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
23 0 obj
<>
endobj
26 0 obj
<>
endobj
50 0 obj
<>
endobj
65 0 obj
<>
endobj
45 0 obj
<>
endobj
77 0 obj
<>
endobj
22 0 obj
[/CalRGB<>]
endobj
78 0 obj
<>
endobj
79 0 obj
<>
endobj
72 0 obj
[80 0 R]
endobj
73 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.06 612 -792 re
W n
BT
/CS0 cs 0 0 0 sc
/T1_0 1 Tf
-0.00011 Tc -0.0024 Tw 10 0 0 10 54 713.1616 Tm
[(associated with thrombosis. Our results reveal that IgA)-192.8 (anti-)]TJ
0 Tc 0 Tw 0 -1.2 TD
(\247)Tj
6.5 0 0 6.5 59 697.8616 Tm
(2)Tj
-0.00011 Tc 0.1377 Tw 10 0 0 10 62.25 701.1616 Tm
(-GPI was most related to the occurrence of thrombosis.)Tj
0.1115 Tw -0.825 -1.2 Td
[(Racial dif)17.7 (ferences were recently reported to play a role in)]TJ
0.2791 Tw T*
(the prevalence, isotype distribution, and clinical signifi-)Tj
0.1559 Tw T*
[(cance of aCL)-369.1 (and anti-\247)]TJ
0 Tc 0 Tw 6.5 0 0 6.5 155.9263 661.8616 Tm
(2)Tj
-0.0002 Tc 10 0 0 10 159.1762 665.1616 Tm
(-GPI)Tj
0 Tc 6.5 0 0 6.5 178.6098 668.4615 Tm
(29,30)Tj
-0.00011 Tc 0.1559 Tw 10 0 0 10 193.2347 665.1616 Tm
[(. )17.7 (T)69.9 (o confirm the role of)]TJ
0 Tw -13.9235 -1.2 Td
[(IgA)-295.3 (anti-\247)]TJ
0 Tc 6.5 0 0 6.5 95.8216 649.8616 Tm
(2)Tj
-0.00011 Tc 0.1001 Tw 10 0 0 10 99.0715 653.1616 Tm
[(-GPI in thrombosis, clinical studies of dif)17.7 (ferent)]TJ
0.02499 Tw -4.5072 -1.2 Td
(races are needed.)Tj
0.0464 Tw 1.2 -1.2 Td
[(W)79.9 (e examined the association between aPL)-259.7 (and the loca-)]TJ
-0.0128 Tw -1.2 -1.2 Td
(tion of thrombosis. Stepwise multivariate logistic regression)Tj
0.12621 Tw T*
(analysis revealed that a history of arterial thrombosis was)Tj
0.005 Tw T*
(associated with IgG aCL, whereas the occurrence of venous)Tj
-0.0374 Tw T*
[(thrombosis was related to IgA)-157.8 (anti-\247)]TJ
0 Tc 0 Tw 6.5 0 0 6.5 197.9163 577.8616 Tm
(2)Tj
-0.00011 Tc -0.0374 Tw 10 0 0 10 201.1663 581.1616 Tm
(-GPI. Guglielmone and)Tj
0 Tw -14.7166 -1.2 Td
(Fernandez)Tj
0 Tc 6.5 0 0 6.5 95.6406 572.4615 Tm
(31)Tj
-0.00011 Tc 0.3726 Tw 10 0 0 10 108.3667 569.1616 Tm
(found no relationship between the site of)Tj
0.0701 Tw -5.4367 -1.2 Td
[(thrombosis and aCL)-283.3 (isotype. On the other hand, )17.7 (T)69.9 (ajima, )]TJ
/T1_1 1 Tf
-0.00031 Tc 0 Tw 23.2783 0 Td
(et)Tj
-0.0002 Tc -23.2783 -1.2 Td
(al)Tj
/T1_0 1 Tf
0 Tc 6.5 0 0 6.5 61.7783 548.4615 Tm
(15)Tj
-0.00011 Tc 0.21381 Tw 10 0 0 10 72.9164 545.1616 Tm
(reported that thrombosis was frequently observed in)Tj
0.0975 Tw -1.8916 -1.2 Td
[(patients with IgG aCL)-310.7 (and LAC, while thrombocytopenia,)]TJ
0.0768 Tw T*
(skin ulcers, chilblain ulcers, and vasculitis were associated)Tj
-0.01891 Tw T*
[(with IgA)-176.3 (aCL. )17.7 (They suggested that patients with IgG aCL)-194.4 (or)]TJ
0.27319 Tw T*
[(LAC might develop thrombosis in lar)17.7 (ger vessels, while)]TJ
0.00681 Tw T*
[(smaller vessels might be involved in patients with IgA)-202 (aCL.)]TJ
0.0388 Tw T*
[(In our study)64.8 (, the reason for the dif)17.7 (ference in the location of)]TJ
0.02499 Tw T*
(thrombosis is unknown and requires further investigation.)Tj
0.00861 Tw 1.2 -1.2 Td
(Of note, 28 \(10.4%\) of 270 patients with SLE were posi-)Tj
0.0321 Tw -1.2 -1.2 Td
(tive for anti-\247)Tj
0 Tc 0 Tw 6.5 0 0 6.5 109.6152 433.8616 Tm
(2)Tj
-0.00011 Tc 0.0321 Tw 10 0 0 10 112.8651 437.1616 Tm
[(-GPI isotypes and negative for )17.7 (VDRL, LAC,)]TJ
0.1174 Tw -5.8865 -1.2 Td
(and IgG aCL. One of these 28 patients, who was positive)Tj
0.28191 Tw T*
[(only for IgA)-477.1 (anti-\247)]TJ
0 Tc 0 Tw 6.5 0 0 6.5 137.7115 409.8616 Tm
(2)Tj
-0.00011 Tc 0.28191 Tw 10 0 0 10 140.9614 413.1616 Tm
[(-GPI, had a thrombotic event. )17.7 (This)]TJ
0.04089 Tw -8.6961 -1.2 Td
(finding is consistent with several studies in which the pres-)Tj
0.0901 Tw T*
[(ence of clinical features of )54.8 (APS in rare cases is associated)]TJ
0.35381 Tw T*
(with a positive anti-\247)Tj
0 Tc 0 Tw 6.5 0 0 6.5 149.3142 373.8616 Tm
(2)Tj
-0.00011 Tc 0.35381 Tw 10 0 0 10 152.5642 377.1616 Tm
[(-GPI assay)64.9 (, but a negative aCL)]TJ
0 Tw -9.8564 -1.2 Td
(assay)Tj
0 Tc 6.5 0 0 6.5 75.6553 368.4616 Tm
(32,33)Tj
-0.00011 Tc 0.2623 Tw 10 0 0 10 90.2801 365.1616 Tm
[(. )17.7 (Therefore, the determination of anti-\247)]TJ
0 Tc 0 Tw 6.5 0 0 6.5 259.5258 361.8616 Tm
(2)Tj
-0.00011 Tc 0.2623 Tw 10 0 0 10 262.7758 365.1616 Tm
(-GPI is)Tj
0.1561 Tw -20.8776 -1.2 Td
[(necessary in patients with SLE or signs of )54.9 (APS who test)]TJ
0.02499 Tw T*
[(negative for aCL)-238.2 (and LAC.)]TJ
0.0087 Tw 1.2 -1.21 Td
[(The IgG aCL)-222 (titers were significantly correlated with the)]TJ
-0.0269 Tw -1.2 -1.21 Td
[(IgG, IgM, and IgA)-168.3 (anti-\247)]TJ
0 Tc 0 Tw 6.5 0 0 6.5 153.447 313.6616 Tm
(2)Tj
-0.00011 Tc -0.0269 Tw 10 0 0 10 156.697 316.9616 Tm
[(-GPI titers to varying degrees. )17.7 (The)]TJ
0 Tw -10.2697 -1.21 Td
[(IgA)-206.6 (anti-\247)]TJ
0 Tc 6.5 0 0 6.5 94.935 301.5616 Tm
(2)Tj
-0.00011 Tc 0.01151 Tw 10 0 0 10 98.185 304.8617 Tm
(-GPI titers were also correlated with the IgG and)Tj
-0.00571 Tw -4.4185 -1.21 Td
(IgM anti-\247)Tj
0 Tc 0 Tw 6.5 0 0 6.5 96.983 289.4616 Tm
(2)Tj
-0.00011 Tc -0.0056 Tw 10 0 0 10 100.233 292.7617 Tm
[(-GPI titers. )17.8 (These results are in good accordance)]TJ
0.02499 Tw -4.6233 -1.21 Td
(with other reports)Tj
0 Tc 0 Tw 6.5 0 0 6.5 125.5816 283.9617 Tm
(13,28)Tj
10 0 0 10 140.2064 280.6617 Tm
(.)Tj
-0.00011 Tc -0.0155 Tw -7.4206 -1.21 Td
[(This study had several limitations. )17.8 (W)79.9 (e did not investigate)]TJ
-0.0226 Tw -1.2 -1.21 Td
(other significant comorbidity factors for thrombosis, such as)Tj
0.1628 Tw 0 -1.21 TD
(hyperlipidemia, diabetes, hypertension, and steroid usage.)Tj
0.03931 Tw T*
(Therefore, we could not eliminate their contributions to the)Tj
0.2448 Tw T*
[(occurrence of thrombosis. Only IgG aCL)-458 (was measured)]TJ
0.11079 Tw T*
[(among 3 aCL)-324 (isotypes; thus, IgG aCL)-324 (was compared to 3)]TJ
0 Tw T*
(anti-\247)Tj
0 Tc 6.5 0 0 6.5 77.3227 192.6617 Tm
(2)Tj
-0.00011 Tc 0.16901 Tw 10 0 0 10 80.5727 195.9617 Tm
(-GPI isotypes in the multivariate analysis. In addi-)Tj
-0.00529 Tw -2.6573 -1.21 Td
(tion, the study had limited power to evaluate some variables)Tj
0.12 Tw T*
(that might be codependent, such as LAC and anti-\247)Tj
0 Tc 0 Tw 6.5 0 0 6.5 268.8166 168.4617 Tm
(2)Tj
-0.0002 Tc 10 0 0 10 272.0666 171.7617 Tm
(-GPI.)Tj
-0.00011 Tc 0.02499 Tw -21.8067 -1.21 Td
(This introduced some biases into the results.)Tj
0.0811 Tw 1.2 -1.2 Td
(Our results suggest that anti-\247)Tj
0 Tc 0 Tw 6.5 0 0 6.5 189.2054 144.3617 Tm
(2)Tj
-0.00011 Tc 0.0811 Tw 10 0 0 10 192.4554 147.6618 Tm
(-GPI isotypes are related)Tj
0.17821 Tw -13.8455 -1.2 Td
(to the occurrence of thrombosis, and that measuring IgA)Tj
0 Tw 0 -1.2 TD
(anti-\247)Tj
0 Tc 6.5 0 0 6.5 77.3227 120.3617 Tm
(2)Tj
-0.00011 Tc 0.3007 Tw 10 0 0 10 80.5727 123.6618 Tm
(-GPI may be important for assessing the risk of)Tj
0.1026 Tw -2.6573 -1.2 Td
(thrombosis, especially venous thrombosis, in patients with)Tj
0.1991 Tw T*
[(SLE. Nevertheless, future prospective studies with lar)17.7 (ger)]TJ
0.00439 Tw T*
(numbers of patients are needed to clarify the significance of)Tj
0 Tw T*
(anti-\247)Tj
0 Tc 6.5 0 0 6.5 77.3227 72.3617 Tm
(2)Tj
-0.0002 Tc 10 0 0 10 80.5727 75.6618 Tm
(-GPI.)Tj
/T1_2 1 Tf
-0.00011 Tc 23.7427 63.75 Td
(ACKNOWLEDGMENT)Tj
/T1_0 1 Tf
0.02499 Tw 8 0 0 8 318 703.1616 Tm
(The authors thank Seon-Joon Kim for his technical assistance.)Tj
/T1_2 1 Tf
0 Tw 10 0 0 10 318 679.1616 Tm
(REFERENCES)Tj
/T1_0 1 Tf
0.02499 Tw 8 0 0 8 325 669.1616 Tm
[(1.)-875.1 (Alarcon-Segovia D, Deleze M, Oria CV)128.8 (, et al. )54.8 (Antiphospholipid)]TJ
1.675 -1.25 Td
(antibodies and the antiphospholipid syndrome in systemic lupus)Tj
0 -1.25 TD
[(erythematosus: )54.8 (A)-220.1 (prospective analysis of 500 consecutive patients.)]TJ
T*
(Medicine 1989;68:353-65.)Tj
-1.675 -1.25 Td
[(2.)-875.1 (Harris EN. )54.8 (Antiphospholipid antibodies. Br J Haematol 1990;)]TJ
0 Tw 1.675 -1.25 Td
(74:1-9.)Tj
0.02499 Tw -1.675 -1.25 Td
[(3.)-875.1 (Petri M. Diagnosis of antiphospholipid antibodies. Rheum Dis Clin)]TJ
0 Tc -0.02991 Tw 1.675 -1.25 Td
[(North Am )-54.9 (1994;20:443-69.)]TJ
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(4.)-875.1 (Roubey RAS. Immunology of the antiphospholipid antibody)]TJ
1.675 -1.25 Td
[(syndrome. )54.8 (Arthritis Rheum 1996;39:1444-54.)]TJ
-1.675 -1.25 Td
[(5.)-875.1 (Love PE, Santoro SA. )54.8 (Antiphospholipid antibodies: anticardiolipin)]TJ
1.675 -1.25 Td
(and the lupus anticoagulant in systemic lupus erythematosus \(SLE\))Tj
T*
[(and in non-SLE disorders. )54.8 (Ann Intern Med 1990;1)36.7 (12:682-98.)]TJ
-1.675 -1.25 Td
[(6.)-875.1 (Harris EN, Chan JK, )54.8 (Asherson RA, )54.8 (Aber )17.7 (VR, Gharavi )54.8 (AE, Hughes)]TJ
1.675 -1.25 Td
[(GR. )17.7 (Thrombosis, recurrent fetal loss, and thrombocytopenia.)]TJ
T*
[(Predictive value of the anticardiolipin antibody test. )54.8 (Arch Intern)]TJ
0 Tc T*
(Med 1986;146:2153-6.)Tj
-0.00011 Tc -1.675 -1.25 Td
[(7.)-875.1 (Ginsbur)17.7 (g KS, Liang MH, Newcomer L, et al. )54.8 (Anticardiolipin anti-)]TJ
1.675 -1.25 Td
[(bodies and the risk for ischemic stroke and venous thrombosis. )54.8 (Ann)]TJ
T*
[(Intern Med 1992;1)36.8 (17:997-1002.)]TJ
-1.675 -1.275 Td
[(8.)-875.1 (McNeil HP)110.7 (, Simpson RJ, Chesterman CN, Krilis SA.)]TJ
1.675 -1.275 Td
(Antiphospholipid antibodies are directed against a complex protein)Tj
0 -1.275 TD
(that includes a lipid-binding inhibitor of coagulation: \247)Tj
0 Tc 0 Tw 5.2 0 0 5.2 515.5384 445.9216 Tm
(2)Tj
8 0 0 8 518.1383 448.5616 Tm
(-)Tj
-0.00011 Tc 0.02499 Tw -22.4673 -1.275 Td
[(glycoprotein I \(apolipoprotein H\). Proc Natl )54.8 (Acad Sci USA)]TJ
0 Tc 0 Tw T*
(1990;87:4120-4.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.275 Td
[(9.)-875.1 (Galli M, Comfurius P)110.7 (, Maassen C, et al. )54.8 (Anticardiolipin antibodies)]TJ
1.675 -1.275 Td
[(directed not to cardiolipin but to a plasma protein cofactor)54.8 (. Lancet)]TJ
0 Tc 0 Tw T*
(1990;335:1544-7.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.275 Td
[(10.)-875.1 (Oosting JD, Derksen RHWM, Bobbink IWG, Hackeng )17.7 (TM, Bouma)]TJ
2.175 -1.275 Td
[(BN, De Groot PG. )54.8 (Antiphospholipid antibodies directed against a)]TJ
T*
(combination of phospholipids and prothrombin, protein C, or)Tj
T*
[(protein S: )54.8 (An explanation for their pathogenic mechanism? Blood)]TJ
0 Tc 0 Tw T*
(1993;81:2618-25.)Tj
-0.00011 Tc 0.02499 Tw -2.1381 -1.275 Td
[(1)36.8 (1)-0.1 (.)-875.1 (Roubey RA, Eisenber)17.7 (g RA, )17.7 (W)39.8 (infield JB. \322Anticardiolipin\323)]TJ
2.1381 -1.275 Td
(autoantibodies recognize \247)Tj
0 Tc 0 Tw 5.2 0 0 5.2 424.5422 323.5217 Tm
(2)Tj
-0.00011 Tc 0.02499 Tw 8 0 0 8 427.1422 326.1617 Tm
(-glycoprotein I in the absence of)Tj
-11.0928 -1.275 Td
(phospholipid. Importance of antigen density and bivalent binding.)Tj
0.275 -1.275 Td
(J Immunol 1994;154:954-60.)Tj
-2.45 -1.275 Td
[(12.)-875.1 (Sugi )17.7 (T)74 (, McIntyre JA. )54.8 (Autoantibodies to phosphatidylethanolamine)]TJ
2.175 -1.275 Td
(\(PE\) recognize a kininogen-PE complex. Blood 1995;86:3083-9.)Tj
-2.175 -1.275 Td
[(13.)-875.1 (T)69.9 (sutsumi )54.8 (A, Matsuura E, Ichikawa K, et al. )54.8 (Antibodies to beta)]TJ
2.175 -1.275 Td
(2-glycoprotein I and clinical manifestations in patients with)Tj
T*
[(systemic lupus erythematosus. )54.8 (Arthritis Rheum 1996;39:1466-74.)]TJ
-2.175 -1.275 Td
[(14.)-875.1 (Roubey RA, Maldonado MA, Byrd SN. Comparison of an enzyme-)]TJ
2.175 -1.275 Td
(linked immunosorbent assay for antibodies to beta 2-glycoprotein I)Tj
T*
[(and a conventional anticardiolipin immunoassay)64.8 (. )54.8 (Arthritis Rheum)]TJ
0 Tc 0 Tw T*
(1996;39:1606-7.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(15.)-875.1 (T)69.9 (ajima C, Suzuki )36.8 (Y)128.9 (, Mizushima )36.8 (Y)128.9 (, Ichikawa )36.8 (Y)128.9 (. Clinical)]TJ
2.175 -1.25 Td
[(significance of immunoglobulin )54.8 (A)-220.1 (antiphospholipid antibodies:)]TJ
0 -1.25 TD
(possible association with skin manifestations and small vessel)Tj
T*
(vasculitis. J Rheumatol 1998;25:1730-6.)Tj
0.00729 Tw -2.175 -1.25 Td
[(16.)-875.1 (Fanopoulos )-17.8 (D, T)69.9 (eodorescu )-17.7 (MR, V)110.8 (a)0.3 (r)17.7 (ga )-17.8 (J, T)69.9 (eodorescu )-17.7 (M. )-17.7 (High)]TJ
0.02499 Tw 2.175 -1.25 Td
[(frequency of abnormal levels of IgA)-220.2 (anti-\247)]TJ
0 Tc 0 Tw 5.2 0 0 5.2 476.4243 151.3217 Tm
(2)Tj
-0.00011 Tc 0.02499 Tw 8 0 0 8 479.0243 153.9617 Tm
(-glycoprotein I)Tj
-17.578 -1.25 Td
(antibodies in patients with systemic lupus erythematosus:)Tj
T*
(relationship with antiphospholipid syndrome. J Rheumatol)Tj
0 Tc 0 Tw T*
(1998;25:675-80.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(17.)-875.1 (V)59.8 (iard JP)110.7 (, )54.8 (Amoura Z, Bach JF)79.7 (. )54.8 (Association of anti-\247)]TJ
0 Tc 0 Tw 5.2 0 0 5.2 502.6685 111.3217 Tm
(2)Tj
-0.00011 Tc 0.02499 Tw 8 0 0 8 505.2684 113.9616 Tm
(-glycoprotein I)Tj
-20.8586 -1.25 Td
(antibodies with lupus-type circulating anticoagulant and thrombosis)Tj
T*
[(in systemic lupus erythematosus. )54.8 (Am J Med 1992;93:181-6.)]TJ
-2.175 -1.25 Td
[(18.)-875.1 (McNally )17.7 (T)74 (, Mackie IJ, Machin SJ, Isenber)17.7 (g DA. Increased levels of)]TJ
0 Tc 0 Tw 2.175 -1.25 Td
(\247)Tj
5.2 0 0 5.2 342.4 71.3217 Tm
(2)Tj
-0.00011 Tc 0.02499 Tw 8 0 0 8 347.2 73.9617 Tm
(glycoprotein-I antigen and \247)Tj
0 Tc 0 Tw 5.2 0 0 5.2 438.6535 71.3217 Tm
(2)Tj
-0.00011 Tc 0.02499 Tw 8 0 0 8 443.4535 73.9617 Tm
(glycoprotein-I binding antibodies)Tj
ET
/CS0 CS 0 0 0 SC
54 54 m
558 54 l
S
BT
/T1_1 1 Tf
8 0 0 8 54.5 38.0174 Tm
[(Lee, et al: )17.7 (Anti-\247)]TJ
0 Tc 0 Tw 5.2 0 0 5.2 109.1586 35.3773 Tm
(2)Tj
-0.00011 Tc 0.02499 Tw 8 0 0 8 111.7586 38.0174 Tm
(-GPI in SLE)Tj
0 Tc 0 Tw 54.2802 -0.2854 Td
(523)Tj
ET
1 1 1 sc
101.25 59.08 407.5 -10.83 re
f*
0.5 w
101.25 59.08 407.5 -10.83 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 g
/GS1 gs
/T1_3 8 Tf
120.092 51 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2001. All rights reserved.)Tj
ET
Q
BT
0 g
/GS1 gs
/T1_4 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS1 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS1 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
37 0 obj
<>
endobj
74 0 obj
<>
endobj
80 0 obj
<>
endobj
81 0 obj
<>
endobj
69 0 obj
[82 0 R]
endobj
70 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.06 612 -792 re
W n
/CS0 CS 0 0 0 SC
54 54 m
558 54 l
S
BT
/CS0 cs 0 0 0 sc
/T1_0 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 424.3613 35.9844 Tm
(The Journal of Rheumatology 2001; 28:3)Tj
0 Tc 0 Tw -46.2952 -0.0313 Td
(522)Tj
ET
1 1 1 sc
102.25 59.08 407.5 -10.83 re
f*
0.5 w
102.25 59.08 407.5 -10.83 re
S
BT
0 0 0 sc
/T1_0 1 Tf
-0.00011 Tc 0.20441 Tw 10 0 0 10 54 257.1687 Tm
[(Relationship between IgG aCL)-436.6 (and anti-\247)]TJ
0 Tc 0 Tw 6.5 0 0 6.5 231.5118 253.8687 Tm
(2)Tj
-0.00011 Tc 0.2043 Tw 10 0 0 10 234.7618 257.1687 Tm
(-GPI isotypes.)Tj
/T1_1 1 Tf
0.33031 Tw -18.0762 -1.2 Td
[(T)35 (iters of IgG aCL)-543.5 (in sera of patients with SLE were)]TJ
0.1884 Tw 0 -1.2 TD
(compared to the anti-\247)Tj
0 Tc 0 Tw 6.5 0 0 6.5 149.8907 229.8687 Tm
(2)Tj
-0.00011 Tc 0.1884 Tw 10 0 0 10 153.1407 233.1687 Tm
[(-GPI isotype titers. )17.7 (The IgG aCL)]TJ
0.1263 Tw -9.9141 -1.2 Td
(values were positively correlated with IgG, IgM, and IgA)Tj
0 Tw T*
(anti-\247)Tj
0 Tc 6.5 0 0 6.5 77.3227 205.8687 Tm
(2)Tj
-0.0002 Tc 0.13811 Tw 10 0 0 10 80.5727 209.1687 Tm
(-GPI \()Tj
/T1_2 1 Tf
0 Tc 0 Tw [-0.3 (\002)]TJ
/T1_1 1 Tf
0.13811 Tw 3.6011 0 Td
(= 0.473, p < 0.001; )Tj
/T1_2 1 Tf
0 Tw [0.1 (\002)]TJ
/T1_1 1 Tf
0.13811 Tw 9.5333 0 Td
[(= 0.464, p)-388.1 (< 0.001; )]TJ
/T1_2 1 Tf
0 Tw -15.7918 -1.2 Td
(\002)Tj
/T1_1 1 Tf
0.02499 Tw 0.8238 0 Td
(= 0.458, p < 0.001\).)Tj
/T1_0 1 Tf
-0.00011 Tc 0.2746 Tw -0.8238 -1.44 Td
[(Relationship between IgA)-506.9 (and IgG or IgM anti-\247)]TJ
0 Tc 0 Tw 6.5 0 0 6.5 268.2671 179.4687 Tm
(2)Tj
-0.0002 Tc 10 0 0 10 271.5171 182.7686 Tm
(-GPI.)Tj
/T1_1 1 Tf
-0.00011 Tc 0.0399 Tw -21.7517 -1.2 Td
[(T)35 (iters of IgA)-235.1 (anti-\247)]TJ
0 Tc 0 Tw 6.5 0 0 6.5 132.3177 167.4687 Tm
(2)Tj
-0.00011 Tc 0.0399 Tw 10 0 0 10 135.5677 170.7686 Tm
(-GPI were compared with those of IgG)Tj
0.08591 Tw -8.1568 -1.2 Td
(and IgM anti-\247)Tj
0 Tc 0 Tw 6.5 0 0 6.5 115.6951 155.4687 Tm
(2)Tj
-0.00011 Tc 0.0681 Tw 10 0 0 10 118.9451 158.7686 Tm
[(-GPI. The )-17.7 (IgA)-281 (anti-\247)]TJ
0 Tc 0 Tw 6.5 0 0 6.5 204.6432 155.4687 Tm
(2)Tj
-0.00011 Tc 0.0858 Tw 10 0 0 10 207.8932 158.7686 Tm
(-GPI titers correlated)Tj
0.22681 Tw -15.3893 -1.2 Td
(positively with the IgG and IgM anti-\247)Tj
0 Tc 0 Tw 6.5 0 0 6.5 222.5667 143.4687 Tm
(2)Tj
-0.0002 Tc 0.22681 Tw 10 0 0 10 225.8167 146.7687 Tm
(-GPI titers \()Tj
/T1_2 1 Tf
0 Tc 0 Tw 5.2288 0 Td
(\002)Tj
/T1_1 1 Tf
1.0256 0 Td
(=)Tj
0.02499 Tw -23.4361 -1.2 Td
(0.367, p < 0.001; )Tj
/T1_2 1 Tf
0 Tw [0.2 (\002)]TJ
/T1_1 1 Tf
0.02499 Tw 8.0156 0 Td
(= 0.677, p < 0.001\).)Tj
/T1_3 1 Tf
-0.00011 Tc 0 Tw -8.0156 -2.4 Td
(DISCUSSION)Tj
/T1_1 1 Tf
0.1284 Tw T*
(It is well known that SLE patients with moderate or high)Tj
0.0713 Tw T*
[(levels of IgG and IgM aCL)-284.6 (are more susceptible to throm-)]TJ
0.1342 Tw T*
(botic events)Tj
0 Tw 6.5 0 0 6.5 103.3814 78.0687 Tm
(5-7)Tj
0.1342 Tw 10 0 0 10 112.0443 74.7687 Tm
[(. However)39.7 (, this does not rule out the possi-)]TJ
0.3102 Tw 20.5956 18.24 Td
[(bility that IgA)-505.3 (aCL)-523.4 (isotypes play a role in thrombotic)]TJ
0.3091 Tw T*
(episodes. Kalunian, )Tj
/T1_0 1 Tf
0.30901 Tw 8.7268 0 Td
(et al)Tj
/T1_1 1 Tf
0 Tc 0 Tw 6.5 0 0 6.5 425.8537 248.4687 Tm
(26)Tj
-0.00011 Tc 0.3091 Tw 10 0 0 10 437.9443 245.1687 Tm
(found a specific association)Tj
-0.0101 Tw -11.9944 -1.2 Td
(between a history of thrombosis and the presence of the IgA)Tj
0.0164 Tw T*
[(aCL)-229.6 (isotype. Gharavi, )]TJ
/T1_0 1 Tf
[-0.3 (et al)]TJ
/T1_1 1 Tf
0 Tc 0 Tw 6.5 0 0 6.5 426.5836 224.4687 Tm
(27)Tj
-0.00011 Tc 0.0163 Tw 10 0 0 10 435.747 221.1687 Tm
(also reported that the presence)Tj
0.0199 Tc 0.35539 Tw -11.7747 -1.2 Td
[(of IgA)-570.5 (aCL)-588.6 (was significantly related to thrombosis.)]TJ
-0.00011 Tc 0.08211 Tw T*
[(Although the concordance between IgA)-277.3 (aCL)-295.4 (and IgA)-277.3 (anti-)]TJ
0 Tc 0 Tw T*
(\247)Tj
6.5 0 0 6.5 323 181.8687 Tm
(2)Tj
-0.00011 Tc 0.1067 Tw 10 0 0 10 326.25 185.1687 Tm
(-GPI appears to be lower than the concordance between)Tj
0.14819 Tw -0.825 -1.2 Td
(the IgG and IgM isotypes in SLE, the occurrence of IgA)Tj
0 Tw T*
(anti-\247)Tj
0 Tc 6.5 0 0 6.5 341.3227 157.8687 Tm
(2)Tj
-0.00011 Tc 0.0396 Tw 10 0 0 10 344.5727 161.1687 Tm
(-GPI was significantly associated with thrombosis in)Tj
0 Tc 0.04601 Tw -2.6573 -1.2 Td
[(the study by )17.8 (T)70 (sutsumi, )]TJ
/T1_0 1 Tf
-0.00011 Tc 9.4571 0 Td
(et al)Tj
/T1_1 1 Tf
0 Tc 0 Tw 6.5 0 0 6.5 430.5264 152.4687 Tm
(28)Tj
-0.00011 Tc 0.04601 Tw 10 0 0 10 437.0263 149.1687 Tm
[(. )17.7 (Their results did not directly)]TJ
0.1483 Tw -11.9026 -1.2 Td
[(prove a relationship between the presence of IgA)-343.5 (anti-\247)]TJ
0 Tc 0 Tw 6.5 0 0 6.5 551.4225 133.8687 Tm
(2)Tj
10 0 0 10 554.6726 137.1687 Tm
(-)Tj
-0.00011 Tc 0.0562 Tw -23.6673 -1.2 Td
(GPI and thrombosis, since most patients who had a history)Tj
0.0575 Tw T*
[(of thrombosis and positive IgA)-252.7 (anti-\247)]TJ
0 Tc 0 Tw 6.5 0 0 6.5 470.5661 109.8687 Tm
(2)Tj
-0.00011 Tc 0.0575 Tw 10 0 0 10 473.816 113.1687 Tm
(-GPI were also posi-)Tj
0.02499 Tw -15.5816 -1.2 Td
(tive for IgG or IgM anti-\247)Tj
0 Tc 0 Tw 6.5 0 0 6.5 422.8145 97.8687 Tm
(2)Tj
-0.0002 Tc 10 0 0 10 426.0645 101.1687 Tm
(-GPI.)Tj
0.0199 Tc 0.42439 Tw -9.6065 -1.2 Td
[(W)79.9 (e used stepwise multivariate logistic regression)]TJ
-0.00011 Tc 0.11729 Tw -1.2 -1.2 Td
(analysis to determine which anti-\247)Tj
0 Tc 0 Tw 6.5 0 0 6.5 460.4199 73.8687 Tm
(2)Tj
-0.00011 Tc 0.11729 Tw 10 0 0 10 463.6699 77.1687 Tm
(-GPI isotype was most)Tj
/T1_0 1 Tf
0 Tc 0.02499 Tw 8 0 0 8 127.0894 713.4311 Tm
[(T)91.9 (able 2. )]TJ
/T1_1 1 Tf
-0.00011 Tc [0.3 (Relationship between antiphospholipid antibodies and a history of thromb\
osis.)]TJ
-0.0298 Tw 11.9159 -2.5 Td
[(Thrombosis )-54.8 (\(%\))-5464.3 (Univariate Analysis)-3499.7 (Multivariate Analysis)]TJ
0.02499 Tw -2.5183 -1.25 Td
[(Y)99.8 (e)0.1 (s)-6636.7 (No)-3695.7 (OR \(95% CI\))-3506.6 (p)-3431.6 (OR \(95% CI\))-2431.6 (p)]TJ
0 Tc -9.3976 -2.5 Td
[(BFP-STS)-4597.4 (6/28 \(21.4\))-2531.6 (21/213 \(9.9\))-2109.5 (2.5 \(0.9\3206.8\))-2550 (0.102)-2509.5 (1.3 \(0.3\3205.1\))-1800 (0.725)]TJ
0 -1.25 TD
[(LAC)-5931.9 (12/27 \(44.4\))-2031.6 (40/201 \(19.9\))-2109.5 (3.2 \(1.4\3207.4\))-2550 (0.007)-2509.5 (0.7 \(0.2\3202.4\))-1800 (0.539)]TJ
T*
[(IgG aCL)-4380.3 (20/28 \(71.4\))-2031.6 (52/216 \(24.1\))-1609.5 (7.9 \(3.3\32019.0\))-1711 (< 0.001)-2009.5 (2.7 \(0.5\32014.4\))-1800 (0.249)]TJ
-0.00011 Tc T*
(IgG anti-\247)Tj
0 Tc 0 Tw 5.2 0 0 5.2 160.3852 630.7911 Tm
(2)Tj
0.0249 Tw 8 0 0 8 162.9851 633.4311 Tm
[(-GPI)-1501.3 (17/24 \(70.8\))-2031.6 (42/131 \(32.1\))-1609.5 (5.1 \(2.0\32013.4\))-1711 (< 0.001)-2009.5 (4.1 \(1.3\32013.2\))-1800 (0.018)]TJ
-0.00011 Tc -4.487 -1.25 Td
(IgM anti-\247)Tj
0 Tc 0 Tw 5.2 0 0 5.2 161.7211 620.7911 Tm
(2)Tj
0.0249 Tw 8 0 0 8 164.3211 623.4311 Tm
[(-GPI)-1834.3 (9/24 \(37.5\))-2531.6 (13/137 \(9.5\))-1609.5 (5.7 \(2.1\32015.6\))-2550 (0.001)-2509.5 (1.4 \(0.4\3205.2\))-1800 (0.614)]TJ
-0.00011 Tc 0 Tw -4.654 -1.25 Td
[(IgA)-220.2 (anti-\247)]TJ
0 Tc 5.2 0 0 5.2 159.9457 610.7911 Tm
(2)Tj
0.0249 Tw 8 0 0 8 162.5457 613.4311 Tm
[(-GPI)-1556.2 (18/24 \(75.0\))-2031.6 (38/137 \(27.7\))-1609.5 (7.8 \(2.9\32021.2\))-1711 (< 0.001)-2009.5 (9.9 \(2.6\32037.2\))-1800 (0.001)]TJ
-0.00011 Tc -4.432 -2.5 Td
(BFP-STS: Biologic false-positive serologic test for syphilis.)Tj
ET
127.51 703.7 m
501.91 703.7 l
129.11 677.3 m
501.71 677.3 l
127.91 606.3 m
502.91 606.3 l
S
BT
/T1_0 1 Tf
0 Tc 8 0 0 8 127.5 564.5293 Tm
[(T)91.9 (able 3. )]TJ
/T1_1 1 Tf
-0.00011 Tc [0.1 (Relationship between antiphospholipid antibodies and a history of arteri\
al thrombosis.)]TJ
-0.0298 Tw 8.727 -2.5 Td
[(Arterial )-37.1 (Thrombosis )-54.8 (\(%\))-4400.1 (Univariate Analysis)-3025.1 (Multivariate Analysis)]TJ
0.02499 Tw 0.5456 -1.25 Td
[(Y)99.8 (e)0.1 (s)-6461.7 (No)-3570.6 (OR \(95% CI\))-3331.6 (p)-2731.6 (OR \(95% CI\))-2831.6 (p)]TJ
0 Tc -9.2726 -2.5 Td
[(BFP-STS)-3931.6 (4/15 \(26.7\))-2831.6 (23/226 \(10.2\))-1320.6 (3.2 \(0.9\32010.9\))-2329.7 (0.072)-1729.7 (3.6 \(0.7\32017.9\))-1848.2 (0.1)36.9 (15)]TJ
T*
[(LAC)-5766.1 (5/15 \(33.3\))-2831.6 (47/213 \(22.1\))-1570.6 (1.8 \(0.6\3205.4\))-2579.7 (0.342)-1979.7 (0.2 \(0.0\3201.1\))-2079.7 (0.058)]TJ
T*
[(IgG aCL)-3964.5 (12/14 \(85.7\))-2581.6 (60/230 \(26.1\))-1070.6 (17.0 \(3.7\32078.2\))-1660.2 (< 0.001)-810.3 (22.6 \(2.6\320196.3\))-1329.7 (0.005)]TJ
-0.00011 Tc T*
(IgG anti-\247)Tj
0 Tc 0 Tw 5.2 0 0 5.2 160.7957 481.8893 Tm
(2)Tj
0.0249 Tw 8 0 0 8 163.3957 484.5293 Tm
[(-GPI)-1085.5 (10/14 \(71.4\))-2581.6 (49/141 \(34.8\))-1320.6 (4.7 \(1.4\32015.7\))-2329.7 (0.010)-1729.7 (3.6 \(0.8\32016.3\))-1829.7 (0.097)]TJ
-0.00011 Tc -4.487 -1.25 Td
(IgM anti-\247)Tj
0 Tc 0 Tw 5.2 0 0 5.2 162.1316 471.8893 Tm
(2)Tj
0.0249 Tw 8 0 0 8 164.7316 474.5293 Tm
[(-GPI)-1168.5 (6/14 \(42.9\))-2831.6 (16/147 \(10.9\))-1320.6 (6.1 \(1.9\32020.0\))-2329.7 (0.005)-1729.7 (2.1 \(0.4\32010.9\))-1829.7 (0.387)]TJ
-0.00011 Tc 0 Tw -4.6539 -1.25 Td
[(IgA)-220.2 (anti-\247)]TJ
0 Tc 5.2 0 0 5.2 160.3563 461.8893 Tm
(2)Tj
0.0249 Tw 8 0 0 8 162.9562 464.5293 Tm
[(-GPI)-1158.9 (1)36.9 (1/14 \(78.6\))-2600.1 (45/147 \(30.6\))-1320.6 (8.3 \(2.2\32031.2\))-2329.7 (0.001)-1729.7 (2.3 \(0.3\32020.7\))-1829.7 (0.442)]TJ
-0.00011 Tc -4.432 -2.5 Td
(BFP-STS: Biologic false-positive serologic test for syphilis.)Tj
ET
127.5 555 m
489.5 555 l
127.5 531.4 m
489.5 531.4 l
127.5 456 m
490.5 456 l
S
BT
/T1_0 1 Tf
0 Tc 8 0 0 8 128 416.6374 Tm
[(T)91.9 (able 4. )]TJ
/T1_1 1 Tf
-0.00011 Tc [0.1 (Relationship between antiphospholipid antibodies and a history of venous\
thrombosis.)]TJ
8.7154 -2.5 Td
[(V)110.8 (enous )17.7 (Thrombosis \(%\) )-3025.1 (Univariate )54.8 (Analysis Multivariate )54.8 (Analysis)]TJ
0.8572 -1.25 Td
[(Y)99.8 (e)0.1 (s)]TJ
7.44148 0 Td
[(No)-4245.6 (OR \(95% CI\))-3231.6 (p)-2231.6 (OR \(95% CI\))-3131.6 (p)]TJ
0 Tc -17.01408 -2.5 Td
[(BFP-STS)-4231.6 (4/15 \(26.7\))-2356.6 (23/226 \(10.2\))-1995.5 (3.2 \(0.9\32010.9\))-2229.7 (0.072)-1479.7 (1.4 \(0.3\3207.0\))-2379.7 (0.676)]TJ
T*
(LAC)Tj
8.0661 0 Td
[(8/14 \(57.1\))-2356.6 (44/214 \(20.6\))-1995.5 (5.2 \(1.7\32015.6\))-2229.7 (0.004)-1229.7 (3.8 \(0.8\32016.8\))-2129.7 (0.081)]TJ
-8.0661 -1.25 Td
[(IgG aCL)-4264.5 (10/16 \(62.5\))-2106.6 (62/228 \(27.2\))-1995.5 (4.5 \(1.6\32012.8\))-2229.7 (0.008)-1479.7 (0.7 \(0.1\3207.1\))-2379.7 (0.738)]TJ
-0.00011 Tc T*
(IgG anti-\247)Tj
0 Tc 0 Tw 5.2 0 0 5.2 161.2957 333.9973 Tm
(2)Tj
0.0249 Tw 8 0 0 8 163.8957 336.6374 Tm
[(-GPI)-1635.5 (8/12 \(66.7\))-2356.6 (51/143 \(35.7\))-1995.5 (3.6 \(1.0\32012.6\))-2229.7 (0.059)-1479.7 (1.7 \(0.4\3208.3\))-2379.7 (0.482)]TJ
-0.00011 Tc -4.487 -1.25 Td
(IgM anti-\247)Tj
0 Tc 0 Tw 5.2 0 0 5.2 162.6316 323.9973 Tm
(2)Tj
0.0249 Tw 8 0 0 8 165.2316 326.6374 Tm
[(-GPI)-1468.5 (4/12 \(33.3\))-2356.6 (18/149 \(12.1\))-1995.5 (3.6 \(1.0\32013.3\))-2229.7 (0.062)-1479.7 (0.8 \(0.2\3203.9\))-2379.7 (0.772)]TJ
-0.00011 Tc 0 Tw -4.6539 -1.25 Td
[(IgA)-220.2 (anti-\247)]TJ
0 Tc 5.2 0 0 5.2 160.8563 313.9973 Tm
(2)Tj
0.0249 Tw 8 0 0 8 163.4562 316.6374 Tm
[(-GPI)-1690.4 (9/12 \(75.0\))-2356.6 (47/149 \(31.5\))-1995.5 (6.5 \(1.7\32025.2\))-2229.7 (0.004)-979.7 (10.5 \(1.2\32090.8\))-1879.7 (0.033)]TJ
-0.00011 Tc -4.432 -2.5 Td
(BFP-STS: Biologic false-positive serologic test for syphilis.)Tj
ET
128 405.9 m
488 405.9 l
S
488.4 381.9 m
128 381.9 l
S
127.6 308.5 m
488 308.5 l
S
Q
Q
q
0 0 612 792 re
W n
BT
0 g
/GS1 gs
/T1_4 8 Tf
120.092 51 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2001. All rights reserved.)Tj
ET
Q
BT
0 g
/GS1 gs
/T1_5 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS1 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS1 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
13 0 obj
<>
endobj
14 0 obj
<>
endobj
15 0 obj
<>stream
HTPn0St䬆wDdyWR x y